Trials / Conditions / Neuroectodermal Tumors

Neuroectodermal Tumors

12 registered clinical trials studyying Neuroectodermal Tumors — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gli NCT05850377	Sociedad de Lucha Contra el Cáncer del Ecuador	—
Recruiting	Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282	Sociedad Española de Medicina Nuclear e Imagen Molecular	—
Unknown	Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. NCT04388033	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 1 / Phase 2
Recruiting	Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082	Jazz Pharmaceuticals	Phase 1
Unknown	A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma NCT03561259	Jubilant DraxImage Inc.	Phase 2
Recruiting	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388	M.D. Anderson Cancer Center	Phase 1
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Completed	Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects NCT02798406	DNAtrix, Inc.	Phase 2
Completed	Trial of Afatinib in Pediatric Tumours NCT02372006	Boehringer Ingelheim	Phase 1 / Phase 2
Unknown	Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic NCT01579253	Ludwig-Maximilians - University of Munich	—
Unknown	Establishment of a Brain and Spinal Tumor Tissue Bank NCT00686387	Taipei Medical University WanFang Hospital	—
Approved For Marketing	Vorasidenib Expanded Access Program NCT05592743	Servier	—